NMDA antagonist treatment of depression

Current Opinion in Neurobiology

Volumn 36, Issue , 2016, Pages 112-117

  Williams, Nolan R ^a   Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; TARGET OF RAPAMYCIN KINASE;

ANTERIOR CINGULATE; ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SYNAPSE; SYNAPTOGENESIS; ANTAGONISTS AND INHIBITORS; BRAIN; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; METABOLISM; SIGNAL TRANSDUCTION;

ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; NEURONAL PLASTICITY; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84949432337     PISSN: 09594388     EISSN: 18736882     Source Type: Journal    
DOI: 10.1016/j.conb.2015.11.001     Document Type: Review

References (92)

1. Williams N., Simpson A.N., Simpson K., Nahas Z. Relapse rates with long-term antidepressant drug therapy: a meta-analysis. Human Psychopharmacol 2009, 24:401-408.
2. Ferrari A.J., Charlson F.J., Norman R.E., et al. Burden of depressive disorders by country, sex, age, and year: findings from the Global Burden of Disease Study 2010. PLoS Med 2013, 10:e1001547.
3. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
4. Schatzberg A.F. Issues encountered in recent attempts to develop novel antidepressant agents. Ann N Y Acad Sci 2015.
5. Berlim M.T., Fleck M.P., Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med 2008, 40:149-159.
6. Howland R.H. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv 2008, 46:21-24.
7. Williams N.R., Taylor J.J., Kerns S., Short E.B., Kantor E.M., George M.S. Interventional psychiatry: why now?. J Clin Psychiatry 2014, 75:895-897.
8. Abdallah C.G., Averill L.A., Krystal J.H. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 2015, 1344:66-77.
9. Berman R.M., Cappiello A., Anand A., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
10. Yamamura T., Harada K., Okamura A., Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-d-aspartate receptor?. Anesthesiology 1990, 72:704-710.
11. Murrough J.W., Iosifescu D.V., Chang L.C., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170:1134-1142.
12. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch General Psychiatry 2006, 63:856-864.
13. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch General Psychiatry 1994, 51:199-214.
14. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997, 7:25-38.
15. Vollenweider F.X., Leenders K.L., Scharfetter C., et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997, 7:9-24.
16. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997, 16:357-372.
17. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
18. Mjellem N., Lund A., Hole K. Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice. Neuropharmacology 1993, 32:591-595.
19. Luckenbaugh D.A., Niciu M.J., Ionescu D.F., et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord 2014, 159:56-61.
20. Mion G., Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 2013, 19:370-380.
21. Zarate C.A., Brutsche N.E., Ibrahim L., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71:939-946.
22. Diazgranados N., Ibrahim L., Brutsche N.E., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010, 67:793-802.
23. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013, 34:287-293.
24. Murrough J.W., Perez A.M., Pillemer S., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013, 74:250-256.
25. Diamond P.R., Farmery A.D., Atkinson S., et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014, 28:536-544.
26. Rasmussen K.G., Lineberry T.W., Galardy C.W., et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013, 27:444-450.
27. Shiroma P.R., Johns B., Kuskowski M., et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014, 155:123-129.
28. Segmiller F., Ruther T., Linhardt A., et al. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 2013, 53:996-998.
29. Schatzberg A.F. A word to the wise about ketamine. Am J Psychiatry 2014, 171:262-264.
30. Citri A., Malenka R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33:18-41.
31. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
32. Holtzheimer P.E., Mayberg H.S. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011, 34:1-9.
33. Gradin V.B., Pomi A. The role of hippocampal atrophy in depression: a neurocomputational approach. J Biol Phys 2008, 34:107-120.
34. Kang H.J., Voleti B., Hajszan T., et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med 2012, 18:1413-1417.
35. Yuen E.Y., Wei J., Liu W., Zhong P., Li X., Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 2012, 73:962-977.
36. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
37. Verhagen M., van der Meij A., van Deurzen P.A., et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010, 15:260-271.
38. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
39. Jernigan C.S., Goswami D.B., Austin M.C., et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1774-1779.
40. Bath K.G., Jing D.Q., Dincheva I., et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 2012, 37:1297-1304.
41. Ota K.T., Liu R.J., Voleti B., et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat Med 2014, 20:531-535.
42. Dwyer J.M., Lepack A.E., Duman R.S. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int J Neuropsychopharmacol 2012, 15:429-434.
43. Abdallah C.G., Sanacora G., Duman R.S., Krystal J.H. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 2015, 66:509-523.
44. Corlett P.R., Honey G.D., Krystal J.H., Fletcher P.C. Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology 2011, 36:294-315.
45. Autry A.E., Adachi M., Nosyreva E., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
46. Anand A., Charney D.S., Oren D.A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry 2000, 57:270-276.
47. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
48. Maeng S., Zarate C.A., Du J., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
49. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012, 71:996-1005.
50. Li N., Lee B., Liu R.J., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
51. Rosenberg D.R., Macmaster F.P., Mirza Y., et al. Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58:700-704.
52. Halari R., Simic M., Pariante C.M., et al. Reduced activation in lateral prefrontal cortex and anterior cingulate during attention and cognitive control functions in medication-naive adolescents with depression compared to controls. J Child Psychol Psychiatry 2009, 50:307-316.
53. Salvadore G., Cornwell B.R., Colon-Rosario V., et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009, 65:289-295.
54. Salvadore G., Cornwell B.R., Sambataro F., et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
55. Lally N., Nugent A.C., Luckenbaugh D.A., Niciu M.J., Roiser J.P., Zarate C.A. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 2015, 29:596-607.
56. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol Psychiatry 2009, 65:181-184.
57. Luckenbaugh D.A., Ibrahim L., Brutsche N., et al. Family history of alcohol dependence and antidepressant response to an N-methyl-d-aspartate antagonist in bipolar depression. Bipolar Disord 2012, 14:880-887.
58. Machado-Vieira R., Yuan P., Brutsche N., et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. J Clin Psychiatry 2009, 70:1662-1666.
59. Rybakowski J.K., Permoda-Osip A., Skibinska M., Adamski R., Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?. Human Psychopharmacol 2013, 28:87-90.
60. Haile C.N., Murrough J.W., Iosifescu D.V., et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014, 17:331-336.
61. Duncan W.C., Sarasso S., Ferrarelli F., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013, 16:301-311.
62. Sanacora G., Schatzberg A.F. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?. Neuropsychopharmacology 2014.
63. Zarate C.A., Singh J.B., Quiroz J.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.
64. Heresco-Levy U., Gelfin G., Bloch B., et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 2013, 16:501-506.
65. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995, 15:49-57.
66. Nyhuis P.W., Gastpar M., Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 2008, 28:593-595.
67. Monteggia L.M., Malenka R.C., Deisseroth K. Depression: the best way forward. Nature 2014, 515:200-201.
68. Nahas Z., Al-Ali K., Sawaya H., Hamadeh A., Bazzi Z., Atoui M., Karameh F. Functional connectivity focal electrically administered seizure therapy (FEAST) using high resolution EEG. Neuropsychopharmacology 2015, 39. S561-S561.
69. Short B., Spicer K., Burns C., Archer M., Schmidt M., Sackeim H., George M., Nahas Z. Ictal perfusion SPECT reveals focal seizures associated with a new form of ECT: focal electrically-administered seizure therapy [FEAST]. Biol Psychiatry 2012, 71. 200S-200S.
70. Chahine G., Short B., Spicer K., et al. Regional cerebral blood flow changes associated with focal electrically administered seizure therapy (FEAST). Brain Stimul 2014, 7:483-485.
71. Hoy K.E., Thomson R.H., Cherk M., Yap K.S., Daskalakis Z.J., Fitzgerald P.B. Effect of magnetic seizure therapy on regional brain glucose metabolism in major depression. Psychiatry Res 2013, 211:169-175.
72. Sun Y.F.F., Blumberger D., Wong W., Daskalakis Z. Magnetic seizure therapy for treatment resistant depression: insights from TMS-EEG measures. Biol Psychiatry 2015, 77:P754.
73. Sackeim H.A., Prudic J., Nobler M.S., et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul 2008, 1:71-83.
74. Nahas Z., Short B., Burns C., et al. A feasibility study of a new method for electrically producing seizures in man: focal electrically administered seizure therapy [FEAST]. Brain Stimul 2013, 6:403-408.
75. Lisanby S.H., Schlaepfer T.E., Fisch H.U., Sackeim H.A. Magnetic seizure therapy of major depression. Arch Gen Psychiatry 2001, 58:303-305.
76. Elfawal M.A., Towler M.J., Reich N.G., Weathers P.J., Rich S.M. Dried whole-plant Artemisia annua slows evolution of malaria drug resistance and overcomes resistance to artemisinin. Proc Natl Acad Sci U S A 2015, 112:821-826.
77. Casali A.G., Gosseries O., Rosanova M., et al. A theoretically based index of consciousness independent of sensory processing and behavior. Sci Transl Med 2013, 5:198ra105.
78. Zarate C.A., Mathews D., Ibrahim L., et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry 2013, 74:257-264.
79. Hustveit O., Maurset A., Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995, 77:355-359.
80. Tan S., Lam W.P., Wai M.S., Yu W.H., Yew D.T. Chronic ketamine administration modulates midbrain dopamine system in mice. PLoS ONE 2012, 7:e43947.
81. Sanacora G., Mason G.F., Rothman D.L., et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003, 160:577-579.
82. Brunoni A.R., Baeken C., Machado-Vieira R., Gattaz W.F., Vanderhasselt M.A. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry 2014, 15:411-418.
83. Duthie A.C., Perrin J.S., Bennett D.M., Currie J., Reid I.C. Anticonvulsant mechanisms of electroconvulsive therapy and relation to therapeutic efficacy. J ECT 2015.
84. Strome E.M., Clark C.M., Zis A.P., Doudet D.J. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: an in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry 2005, 57:1004-1010.
85. McDonald W.M., Greenberg B.D. Electroconvulsive therapy in the treatment of neuropsychiatric conditions and transcranial magnetic stimulation as a pathophysiological probe in neuropsychiatry. Depress Anxiety 2000, 12:135-143.
86. Feder A., Parides M.K., Murrough J.W., et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014, 71:681-688.
87. Dakwar E., Levin F., Foltin R.W., Nunes E.V., Hart C.L. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry 2014, 76:40-46.
88. Rodriguez C.I., Kegeles L.S., Levinson A., et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013, 38:2475-2483.
89. Corp S.A., Gitlin M.J., Altshuler L.L. A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder. J Clin Psychiatry 2014, 75:1010-1018.
90. Taylor J.J.W.N., George M.S. Beyond neural cubism: promoting a multidimensional view of brain disorders by enhancing the integration of neurology and psychiatry in education. Acad Med 2015, 90:581-586.
91. Vogt B.A., Wiley R.G., Jensen E.L. Localization of Mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of Mu regulation. Exp Neurol 1995, 135:83-92.
92. Goodkind M., Eickhoff S.B., Oathes D.J., et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 2015, 72:305-315.